Recent retrospective studies of heterogeneously treated patients have suggested that chromosomal aberrations of the MYC gene locus indicate an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL). Here, we investigated the prognostic impact of MYC aberrations analyzed by interphase fluorescence in situ hybridization in 177 patients with de novo DLBCL treated within the two prospective, randomized trials non-Hodgkin's lymphoma NHL-B1 and NHL-B2. MYC aberrations were detected in 14 DLBCL (7.9%). In a univariate analysis compared with MYC-negative DLBCL, MYC-positive cases showed a significantly shorter overall survival (OS) (P ¼ 0.047) and relevantly, though not significantly, shorter event-free survival (EFS) (P ¼ 0.062). In a Cox model adjusted for the international prognostic index, the presence of a MYC gene rearrangement was the strongest statistically independent predictor of OS (relative risk 3.4, P ¼ 0.004) and EFS (relative risk 2.5, P ¼ 0.015), and this also held true when the cellof-origin signature detected by immunohistochemistry was included in the model.
Introduction
Diffuse large B-cell lymphomas (DLBCLs) are a group of morphologically, clinically and genetically heterogeneous B-cell non-Hodgkin's lymphomas (NHLs). 1 Immuno-chemotherapy including anti-CD20 antibody has substantially improved the outcome of these lymphomas. 2, 3 However, the course of the disease is still heterogeneous and a subset of patients die within 1 year after the initial diagnosis.
Several attempts have been made to divide DLBCLs into clinically relevant groups by morphological subtyping, 4 clinical scores, 5 immunohistochemical markers 6 and genetic abberations. 7, 8 So far, the international prognostic index 5 has been shown to be the most powerful tool for predicting the clinical outcome in DLBCL and has been confirmed under study conditions. 9 Nevertheless, as the majority of patients will be cured with the current highly effective immuno-chemotherapy protocols, 9 it becomes increasingly essential to identify patients at high risk for treatment failure before primary therapy.
Gene expression profiling allows DLBCL to be subdivided into a germinal-center subtype (GCB) and an activated B-cell subtype, the former being associated with a favorable outcome (cell-of-origin signature). 10 Moreover, we and others have recently shown by gene expression profiling that a subset of DLBCL shares the molecular signature of Burkitt lymphoma (mBL) and that these carry alterations of the MYC locus. 11, 12 On the other hand, molecular profiling demonstrated that chromosomal aberrations affecting the MYC gene locus (MYC positive) also occur in a subset of mature aggressive B-cell lymphomas lacking the mBL signature. Morphologically, these neoplasias mostly resemble DLBCL according to the current WHO classification. 11, 12 Finally, these retrospective analyses showed that in patients treated with anthracyclin-containing chemotherapy protocols, these MYC-positive mature aggressive B-cell lymphomas lacking the mBL signature were associated with an unfavorable clinical course compared to MYC-negative nonmBL. Nevertheless, this study as well as others which did not detect a negative prognostic impact of MYC gene rearrangements in DLBCL were limited by the heterogeneity of treatment and its retrospective nature. 7, 11, 12, 13 Therefore, we tested the prognostic impact of chromosomal aberrations affecting the MYC gene locus in a large cohort of DLBCL treated within two prospective randomized trials taking into account well-established clinical risk factors as well as the cell-of-origin signature, as determined by immunohistochemistry.
Materials and methods

Patients
This study was performed according to the rules of the Helsinki declaration. The clinical protocol and the translational investigations as presented in this study had been approved by the ethical review board of all participating centers. All patients gave written informed consent.
Tissue microarrays were constructed from paraffin blocks as described.
14 All patients were treated within the trials NHL-B1 and NHL-B2 of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) and received CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or CHOEP (CHOP plus etoposide) therapy in a 2 or 3 weekly scheme. Of the patients treated in the NHL-B1 and NHL-B2 trials, respectively, only patients with de novo DLBCL according to the WHO classification 1 were analyzed in this study.
Interphase cytogenetic analyses
Chromosomal aberrations affecting the MYC locus in 8q24 were detected by interphase fluorescence in situ hybridization using the LSI MYC BAP (break-apart) probe (Abbott/Vysis, Wiesbaden, Germany) as described recently. 11, 15 The LSI MYC BAP probe consists of the SpectrumOrange-labeled 5 0 LSI MYC probe that begins 119 kb upstream of the 5 0 end of MYC and extends 266 kb toward the centromere. The SpectrumGreen 3 0 LSI MYC probe starts about 1.5 Mb 3 0 of MYC and extends toward the telomere for 407 kb. Hybridization protocols and evaluation criteria have been published previously. 15 
Immunohistochemistry
Immunohistochemistry for CD20, CD10, CD5, BCL-2, BCL-6, Ki-67, Mum-1 and HLA-DR was performed on the tissue microarrays in two laboratories and evaluated by one observer. The stainings were scored semiquantitatively as negative, positive or not assessable for CD20, CD10, CD5 and HLA-DR; p25%, 425% positive tumor cells for BCL-2, BCL-6, Mum-1 and Ki-67.
Statistical analysis
Fisher's exact test was used to test for differences in the frequencies between groups.
Event-free survival (EFS) was defined as time from first day of therapy to progressive disease under therapy, or failure to achieve CR or Cru, additional therapy, relapse or death from any cause. 16, 17 Overall survival (OS) was defined as time from first day of therapy to death from any cause. 16, 17 Patients without an Table 1 Clinical, morphological and immunohistochemical characteristics of MYC-positive and MYC-negative DLBCLs 
Results and discussion
Using tissue microarrays, we obtained an informative cytogenetic results for the MYC locus in 177 DLBCL (93 DLBCL were not assessable). The clinical features of the patient cohort analyzed in this study was representative for all NHL-B1 and NHL-B2 patients (data not shown). Among the 177 lymphomas, 14 (7.9%) cases showed signal patterns indicating a chromosomal aberration in the MYC locus (MYC positive). This percentage is comparable to other studies. 7, 13 A comparison of the clinical parameters and the immunohistochemical results between the MYC-positive and the MYC-negative lymphomas is shown in Table 1 . MYC-positive lymphomas were more frequently MUM-1 negative, CD10 positive and of the GCB phenotype than MYC-negative DLBCL applying the cell-of-origin signature by immunohistochemistry 18 compared to MYC-negative cases (70.0 and 34.5%, P ¼ 0.038; 71.4 and 34.7%, P ¼ 0.009, 78 and 50%, P ¼ 0.046, respectively, Table 1 ). Although this consistent CD10 expression might suggest some overlap with mBL, we do not believe that a substantial number of lymphomas in the MYC-positive group represent morphologic DLBCL with mBL signature for the following reasons. The majority (84.6%, 11 of 13) of MYCpositive lymphomas in the present series expressed BCL2 and 45.5% (5 of 11) of cases displayed a proliferation index of o75%, features considered to be rather uncommon in mBL 11 ( Table 1) .
Although MYC-positive DLBCL showed significantly more often a low-risk prognostic index (Table 1) , the outcome as assessed by EFS or OS of the MYC-positive DLBCL was worse than the MYC-negative DLBCL (P ¼ 0.047 for OS and P ¼ 0.062 for EFS, Figures 1a and b) . The prognostic importance of aberrations of MYC-locus held true when the GCB/non-GCB phenotype distinction based on immunohistochemistry was additionally included in analyses 18 (P ¼ 0.007 for OS and P ¼ 0.013 for EFS, Figures 1c and d) .
In a Cox analysis adjusting for the prognostic index parameters lactate dehydrogenase, age, Ann Arbor stage and extranodal involvement, MYC aberrations turned out to be the strongest independent predictor (relative risk 3.4, P ¼ 0.004 for OS and 2.5, P ¼ 0.015 for EFS, Supplemantary Table S1 ), and this also held true when the GCB/non-GCB phenotype distinction based on immunohistochemistry was additionally included in the model. Non-GCB-type carried a worse prognosis than GCB-type; however, MYC-positive had a worse outcome compared to the non-GCB (for OS relative risk 1.7 and 2.4, accordingly, Supplemantary Table S2 ). In summary, by using interphase cytogenetics on a large cohort of DLBCL using a widely available fluorescence in situ hybridization assay, we detected chromosomal alterations affecting the MYC locus in almost 8% of cases. Importantly, in this cohort of patients treated within prospective randomized trials, we identified chromosomal alterations affecting the MYC locus as a strong predictor of adverse prognosis independent of prognostic index risk factors and cell-of-origin. Thus, MYC gene rearrangements characterize a small subgroup of DLBCL with a poor outcome in patients treated with CHOP-like regimens. Future studies will have to evaluate the prognostic whether the impact of MYC gene rearrangements will prevail in the rituximab era.
